Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab

• Published in: Polish journal of veterinary sciences Vol. 26; no. 2; pp. 231 - 238
• Main Authors: Calesso, J R, Marques, V S, de Carvalho, O V, Costa-Val, A P
• Format: Journal Article
• Language: English; Polish
• Published: Germany Polish Academy of Sciences, Committee of Veterinary Sciences 01.06.2023
• Subjects: Alopecia; Atopic dermatitis; Baldness; Blood; Cytokines; Dermatitis; Disease; Dogs; Eczema; Erythema; Infections; Monoclonal antibodies; Pathogenesis; Pruritus; Skin diseases; Skin lesions; Variables; Veterinary medicine; pruritus; atopic dermatitis; interleukin-31; monoclonal antibody; lokivetmab
• ISSN: 1505-1773; 2300-2557
• DOI: 10.24425/pjvs.2023.145027

Studies on serum interleukin (IL)-31 levels in dogs with atopic dermatitis (AD) and their correlation with disease severity are limited. To the author's knowledge, there are no studies that measured serum IL-31 in dogs treated with lokivetmab injections, a selective inhibitor of this key cytokine in pruritus. The aim of the study was to evaluate serum IL-31 levels in dogs treated with lokivetmab and correlate it with the severity of canine atopic dermatitis using the pruritus visual analog scale (pVAS) and canine atopic dermatitis extent and severity index (CADESI-04). Ten client-owned dogs diagnosed with AD received two injections of lokivetmab four weeks apart. Disease severity was assessed using the pVAS and CADESI-04 scores before and after both injections. In addition, canine serum IL-31 levels were measured at the same moments. Serum IL-31 was detected in all dogs in the study. There was a significant reduction in pVAS scores and serum IL-31 after administrations. However, there was no difference in CADESI-04 scores, and there was no significant correlation between CADESI-04 scores and serum IL-31 in dogs diagnosed with AD. Nonetheless, a significant positive correlation was observed between the pVAS scores and serum IL-31 levels with lokivetmab therapy, which reinforces the role of IL-31 in the pathogenesis of pruritus in dogs with AD. The data presented here provide further evidence that IL-31 is directly involved in pruritus pathogenesis in dogs with AD. In addition, blocking IL-31 has a significant antipruritic effect, but has no influence on skin lesion severity and extension.